Successful Treatment of Ovarian Cancer Metastasis Using Electrochemotherapy with the Pars Tarava Device
Cancer continues to challenge global health systems, particularly in cases where conventional therapies fall short. New, targeted treatments are becoming increasingly necessary for advanced or inoperable tumors. One such promising approach is electrochemotherapy (ECT), a technique that combines chemotherapy with short, intense electric pulses to enhance the penetration of drugs into cancer cells. Unlike traditional methods, ECT enhances the effectiveness of drugs like bleomycin by temporarily increasing the permeability of tumor cells.
.
What is Electrochemotherapy?
ECT uses electric fields to briefly disrupt cell membranes, enabling higher drug uptake inside malignant cells. After injecting an anti-cancer agent—often bleomycin—directly into or around the tumor, electric pulses are applied using specialized electrodes. This drastically increases the drug’s cytotoxic impact on cancer cells while sparing healthy tissue. Scientific studies show that bleomycin’s potency is increased by 300–700 times through ECT, making it particularly effective for skin and subcutaneous metastases.
.
Case Overview: Localized Tumor from Ovarian Cancer
A 45-year-old woman from Tehran presented with a secondary tumor originating from ovarian cancer, located just beneath the neck on the sternum. Due to its placement, surgery wasn’t a viable option. The treatment began with a direct injection of bleomycin into the tumor, followed by pulsed electric fields administered by the Pars Tarava ECT device to cover the entire mass.
The procedure was done under local anesthesia, with mild muscular contractions during pulse application—a known and harmless side effect. Swelling around the tumor site was minimal and subsided within days. Electrodes were placed strategically to ensure full electric field coverage of the tumor volume.
.
Visible Results After 22 Days
Twenty-two days post-treatment, follow-up evaluation showed a significant tumor size reduction—from 7 cm down to 5 cm, equating to a 63% volume decrease. These results are consistent with existing medical literature, which confirms ECT’s ability to shrink even drug-resistant tumors quickly and effectively.
.
Conclusion: ECT as a Powerful Alternative
This case illustrates how electrochemotherapy can yield substantial results even for complex, non-operable tumors. The Pars Trava system allowed for a focused and minimally invasive intervention, producing rapid tumor shrinkage without systemic side effects. Given its safety profile and proven outcomes, ECT stands out as a reliable solution for patients who have exhausted traditional treatment options.
If you or someone you know is interested in consultation, receiving product catalogs, or purchasing the Pars Tarava electrochemotherapy device, feel free to contact us at +98 902 405 1862 or reach out via WhatsApp. We’re here to support you every step of the way.
